[BIC-announce] FW: Killam Lecture - Monday, March 28, 2011 Lysophospholipid Receptors: Roles in the CNS and Multiple Sclerosis

[Jennifer Chew, Ms.]

PLEASE DISCARD IF THIS IS A DUPLICATE.  THANK YOU.  Jennifer 
 

Jennifer Chew

McConnell Brain Imaging Centre

MNI - WB317

3801 University Street

Montreal, Qc  H3A 2B4

Telephone:  514-398-8554

Fax:  514-398-2975

 

 

________________________________

From: MNISTAFF - Montreal Neurological Institute Staff [mailto:MNISTAFF at LISTS.MCGILL.CA] On Behalf Of Enza Ferracane, Ms.
Sent: Friday, March 25, 2011 10:54 AM
To: MNISTAFF at LISTS.MCGILL.CA
Subject: Killam Lecture - Monday, March 28, 2011



Killam Lecture

 

Speaker:  Jerold Chun, PhD

Department of Pharmacology

Scripps Research Institute, University of California, San Diego

 

Title:  Lysophospholipid Receptors:  Roles in the CNS and Multiple Sclerosis

 

Date:  Monday, March 28, 2011

 

Time:  4pm

 

Place:  de Grandpre Communications Centre

============================================

Jerold Chun is a professor in the Department of Molecular Biology at the Scripps Research Institute and adjunct professor at UCSD. His Killam presentation will focus on his leading edge studies of the receptor-mediated effects of naturally occurring lysophopholipids, namely lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P). The S1P receptor agonist FTY720 has just been approved as a clinical therapy for relapsing forms of multiple sclerosis based on its observed immunologic actions. The drug readily accesses the CNS. His presentation will review the mechanisms of action of FTY on the immune systems and detail his recent studies that used genetic manipulation of S1P receptor on glial cells to show how modulating S1P receptor signaling can impact both on tissue injury and repair within the CNS. 

 

1.The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. <http://www.ncbi.nlm.nih.gov/pubmed/21339490>  Soliven B, Miron V, Chun J.  Neurology. 2011 Feb 22;76(8 Suppl 3):S9-14. 

 

2.FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. <http://www.ncbi.nlm.nih.gov/pubmed/21177428>    Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6  

 

 

Enza Ferracane

Montreal Neurological Institute

3801 University

Montreal, Quebec  H3A 2B4

Director's Office, Rm 636

Tel: (514) 398-1903

Fax:  (514) 398-8248

Email: enza.ferracane at mcgill.ca <mailto:enza.ferracane at mcgill.ca>